NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Cash Flow-to-Debt Ratio
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Cash Flow-to-Debt Ratio of -0.56x as of September 2025, meaning its operating cash flow of $-32.77 Million could theoretically repay -1% of its total liabilities ($58.36 Million) in one year. See NewAmsterdam Pharma Company N.V. Ordinar financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NewAmsterdam Pharma Company N.V. Ordinary Shares Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for NewAmsterdam Pharma Company N.V. Ordinary Shares across 5 annual periods. For the full cash flow conversion analysis, see NewAmsterdam Pharma Company N.V. Ordinar operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Year-by-year debt coverage analysis for NewAmsterdam Pharma Company N.V. Ordinary Shares. Check NewAmsterdam Pharma Company N.V. Ordinar (NAMS) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.48x | $-158.56 Million | $107.12 Million | ▲ +38.5% |
| 2023 | -2.41x | $-141.22 Million | $58.70 Million | ▼ -1192.4% |
| 2022 | 0.22x | $10.66 Million | $48.43 Million | ▲ +108.5% |
| 2021 | -2.60x | $-29.51 Million | $11.36 Million | ▼ -338.9% |
| 2020 | -0.59x | $-7.34 Million | $12.41 Million | — |